Anthony E. Maida III, PhD, MA, MBA

Articles by Anthony E. Maida III, PhD, MA, MBA

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

Latest Updated Articles

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma

Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation

Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM

Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy